Eli Lilly/LLY

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About Eli Lilly

Eli Lilly and Company is engaged in drug manufacturing businesses. The Company discovers, develops, manufactures and markets products in the human pharmaceutical products segment. Its diabetes, obesity and other cardiometabolic products include Basaglar, Humalog, Humulin, Jardiance, Mounjaro, Trulicity and Zepbound. Its oncology products include Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt and Verzenio. Its immunology products include Ebglyss, Olumiant, Omvoh and Taltz. Its neuroscience products include Cymbalta and Emgality. Its other products and therapies include Cialis and Forteo. The Company manufactures and distributes its products through facilities in the United States (U.S.), including Puerto Rico, and in Europe and Asia. The Company, through its subsidiary, POINT Biopharma Global Inc., is engaged in radiopharmaceutical discovery, development, and manufacturing, as well as clinical and pre-clinical radioligand therapies in development for the treatment of cancer.

Ticker

LLY

Sector

Healthcare

Trading on

NYSE

Industry

Biotechnology & Drugs

CEO

David Ricks

Employees

43,000

Headquarters

Indianapolis, United States

Eli Lilly Metrics

BasicAdvanced
$780B
Market cap
120.75
P/E ratio
$6.79
EPS
0.36
Beta
$4.69
Dividend rate
0.63%
Dividend yield
$780B
0.36337
$826.21
$432.34
2.7M
$4.69
1.354
1.026
191.692
204.582
71.20%
30.83%
10.48%
51.15%
14.92%
120.749
21.698
60.852
702.139
1.14%
0.57%
0.63%
29.76%
7.85%
11.62%
-5.10%
15.15%

What the Analysts think about Eli Lilly

Analyst Ratings

Majority rating from 29 analysts.
Buy

Eli Lilly Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
25.58% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$8.8B
-6.26%
Net income
$2.2B
2.43%
Profit margin
25.58%
9.27%

Eli Lilly Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 4.95%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
$2.11
$0.10
$2.49
$2.58
-
Expected
$1.98
-$0.13
$2.22
$2.46
$2.75
Surprise
6.60%
-174.32%
12.22%
4.95%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
Market closedNon-fractional

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Eli Lilly stock?

Eli Lilly (LLY) has a market cap of $780B as of June 20, 2024.

What is the P/E ratio for Eli Lilly stock?

The price to earnings (P/E) ratio for Eli Lilly (LLY) stock is 120.75 as of June 20, 2024.

Does Eli Lilly stock pay dividends?

Yes, the Eli Lilly (LLY) stock pays dividends to shareholders. As of June 20, 2024, the dividend rate is $4.69 and the yield is 0.63%. Eli Lilly has a payout ratio of 71.2% on a trailing twelve-month basis.

When is the next Eli Lilly dividend payment date?

The next Eli Lilly (LLY) dividend payment date is unconfirmed.

What is the beta indicator for Eli Lilly?

Eli Lilly (LLY) has a beta rating of 0.36. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

Buy or sell Eli Lilly stock

Buy or sell Eli Lilly stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing